Sanyuan Sun

机构：Xuzhou Medical College, Affiliated Hospital of Xuzhou Medical College, Xuzhou Central Hospital · ORCID：0000-0002-7477-7491

发表论文 61 篇 · 总被引 2014 次 · h-index 22

代表论文

• Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study (2021 · The Lancet Respiratory Medicine · 被引 206)
• First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer (2025 · JAMA · 被引 71)
• LBA79 GEMSTONE-303: Prespecified progression-free survival (PFS) and overall survival (OS) final analyses of a phase III study of sugemalimab plus chemotherapy vs placebo plus chemotherapy in treatment-naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (2023 · Annals of Oncology · 被引 31)
• Efficacy, Safety, and Immunogenicity of HLX04Versus Reference Bevacizumab in Combination with XELOX or mFOLFOX6 as First-Line Treatmentfor Metastatic Colorectal Cancer: Results of a Randomized, Double-Blind Phase IIIStudy (2021 · BioDrugs · 被引 29)
• Long-Term Efficacy, Safety, and Subgroup Analysis of Savolitinib in Chinese Patients With NSCLCs Harboring MET Exon 14 Skipping Alterations (2022 · JTO Clinical and Research Reports · 被引 27)
• Circulating tumour DNA biomarkers in savolitinib-treated patients with non-small cell lung cancer harbouring MET exon 14 skipping alterations: a post hoc analysis of a pivotal phase 2 study (2022 · Therapeutic Advances in Medical Oncology · 被引 16)